Effectiveness of Exenatide Plus Dapagliflozin on 24 Hour Glucose Variability Measured by CGM. A Proof of Concept.

NCT03970044 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

67

Enrollment

OTHER

Sponsor class

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG: Exenatide 2 MG
DRUG: Dapagliflozin 10 MG

Sponsor

Consano Clinical Research, LLC